(TX_CURR_NAT / SUBNAT) Percentage of adults and children receiving antiretroviral therapy
ART coverage is the second 90 of the global target, and an important step in ending the AIDS epidemic. Antiretroviral therapy has been shown to reduce HIV-related morbidity and mortality among those living with HIV, and onward HIV transmission. Studies have also shown that early initiation, regardless of an individual’s CD4 cell count, can enhance treatment benefits and save lives, and WHO currently recommends treatment for all. The percentage of adults and children receiving antiretroviral therapy among all adults and children living with HIV provides a benchmark for monitoring global targets over time, and comparing progress across countries. It is one of the 10 global indicators in WHO’s 2015 Consolidated strategic information guidelines for HIV in the health sector.
This indicator is harmonized with GARPR indicator 4.1 (https://aidsreportingtool.unaids.org/static/docs/GARPR_Guidelines_2016_E...).
The number of adults and children on ART at the end of the reporting period.
The estimated number of adults and children living with HIV (PLHIV Estimate).
This indicator measures the progress towards providing antiretroviral therapy to all people living with HIV. The data source for this indicator is ART program monitoring tools, such as ART patient registers, pharmacy dispensing records, and summary reporting forms.
The number of adults and children receiving treatment can be obtained through data from facility- based antiretroviral therapy registers or drug supply management systems. Data should be collected continuously and aggregated on a monthly or quarterly basis to obtain subnational and national totals. The most recent full year of data should be used for annual reporting. Data should be collected from health facility recording and reporting forms, program data, health information system.
This indicator can be generated by counting the number of adults and children receiving antiretroviral therapy at the end of the reporting period. This value should equal the number of adults and children who have ever started antiretroviral therapy minus those not currently on treatment prior to the end of the reporting period. This will exclude those who died, stopped treatment or were lost to follow-up during the year.
Some people pick up several months of antiretroviral medicines (ARVs) at one visit, which could cover the last months of the reporting period. Efforts should be made to include these people in the numerator as receiving anti-retrovirals even if they do not attend the clinic in the last month of the reporting period.
When disaggregating the numerator by age, people receiving antiretroviral therapy should be reported in the relevant age category based on their age at the end of the reporting year. HIV- positive pregnant women who are on antiretroviral therapy should be included in the numerator.
People receiving antiretroviral therapy in the private and public sectors should be included where data are available.
Disaggregation: Disaggregated data is required. If data is available use the Age/ex disaggregates, if not available use the Sex disaggregate. Do not enter both.$
- Sex: Male, Female
- Coarse Age/Sex Disag: Female<15, Male <15, Female 15+, Male 15+
Denominatoris not collected as part of indicator, butrather is calculatedfromPLHIV_NATnumerator
(see PLHIV_NAT/SUBNAT for more details)
To adequately plan the ART program, these numbers are needed from both the National and subnational level. The subnational level is considered that in which the country team has prioritized their program (PSNU).
This data should be entered for all SNUs, regardless of PEPFAR funding supporting these geographical areas; so that the total of the sub-National number should equal the total number of National number.
This data should be entered by the country team at both National and Sub-National level by the USG PEPFAR team
Narratives should include information on how National and subnational have been derived for both results and targets.
Host country teams often set targets by OU, and SNU level to plan their programs (please describe the target setting process that the host country employs in the narratives). Targets should aligned with the 90-90-90 UNAIDS HIV response initiative. If the host country does not develop targets for this indicator, then for planning purposes, data should be entered that includes MOH results from the previous reporting with the PEPFAR planned targets (at the least) should constitute the host country targets.